Ann: Updated Company Presentation, page-2

Nice re-release of the old company presentation - can't see anything different aside from 50% patient enrolment as released the other day ?

Has the lagging dates out to Q3 for final dosing on slower than expected enrolment but that was expected for a long time - still get the feeling it could end up 50/50 that it actually goes out to Q4 with them still needing to find another 2 patients followed by prep and then 6 months dosing - should def get at least preliminary data Q3 imo . Always hard to make recruitment numbers in rare diseases hence why they get such small numbers required for trials.

Not sure about 1103 Acromegaly EA hard to read when that will materialise it's been stalled for a while.